Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Dimitri Livitz et al.|Nature Medicine|2019Cited by 521
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R. Parikh, Ryan B. Corcoran, Emily E. Van Seventer et al.|Clinical Cancer Research|2021Cited by 358
Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine TumorsJennifer A. Chan, Matthew H. Kulke, Keith Stuart et al.|Journal of Clinical Oncology|2012Cited by 301